Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen, Inc. | 0.48% | 246.73 | 1.5% | $893.73m | |
| MRNA | Moderna, Inc. | 3.73% | 155.54 | 0.0% | $852.62m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.58% | 288.98 | 1.9% | $508.85m | |
| GILD | Gilead Sciences, Inc. | -0.03% | 62.34 | 1.0% | $477.30m | |
| NVAX | Novavax, Inc. | 12.49% | 64.29 | 75.7% | $468.89m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.20% | 596.56 | 2.6% | $452.80m | |
| ILMN | Illumina, Inc. | 1.04% | 193.02 | 3.3% | $357.64m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 3.00% | 3.78 | 0.7% | $264.24m | |
| BIIB | Biogen, Inc. | 0.93% | 212.58 | 1.8% | $245.16m | |
| BNTX | BioNTech SE | 2.24% | 161.03 | 0.0% | $215.97m | |
| CRSP | CRISPR Therapeutics AG | 10.68% | 70.60 | 0.6% | $192.52m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 1.62% | 86.36 | 4.2% | $117.47m | |
| EXAS | EXACT Sciences Corp. | 7.95% | 44.40 | 17.7% | $102.51m | |
| NTLA | Intellia Therapeutics, Inc. | 16.98% | 63.18 | 2.2% | $99.79m | |
| AXSM | Axsome Therapeutics, Inc. | 1.40% | 41.21 | 1.8% | $99.33m |
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.